222 related articles for article (PubMed ID: 8408472)
1. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors.
Hershkovitz E; Marbach M; Bosin E; Levy J; Roberts CT; LeRoith D; Schally AV; Sharoni Y
J Clin Endocrinol Metab; 1993 Oct; 77(4):963-8. PubMed ID: 8408472
[TBL] [Abstract][Full Text] [Related]
2. Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75.
Kleinman D; Roberts CT; LeRoith D; Schally AV; Levy J; Sharoni Y
Regul Pept; 1993 Oct; 48(1-2):91-8. PubMed ID: 8265821
[TBL] [Abstract][Full Text] [Related]
3. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor.
Osborne CK; Coronado EB; Kitten LJ; Arteaga CI; Fuqua SA; Ramasharma K; Marshall M; Li CH
Mol Endocrinol; 1989 Nov; 3(11):1701-9. PubMed ID: 2558302
[TBL] [Abstract][Full Text] [Related]
5. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
6. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells.
Figueroa JA; Sharma J; Jackson JG; McDermott MJ; Hilsenbeck SG; Yee D
J Cell Physiol; 1993 Nov; 157(2):229-36. PubMed ID: 7693722
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells.
Marelli MM; Moretti RM; Dondi D; Motta M; Limonta P
Endocrinology; 1999 Jan; 140(1):329-34. PubMed ID: 9886842
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells.
Bentel JM; Lebwohl DE; Cullen KJ; Rubin MS; Rosen N; Mendelsohn J; Miller WH
J Cell Physiol; 1995 Oct; 165(1):212-21. PubMed ID: 7559803
[TBL] [Abstract][Full Text] [Related]
9. Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines.
Cappelletti V; Miodini P; Fioravanti L; Di Fronzo G
Anticancer Res; 1995; 15(6B):2551-5. PubMed ID: 8669822
[TBL] [Abstract][Full Text] [Related]
10. Permissive role of polyamines in the cooperative action of estrogens and insulin or insulin-like growth factor I on human breast cancer cell growth.
Huber M; Poulin R
J Clin Endocrinol Metab; 1996 Jan; 81(1):113-23. PubMed ID: 8550737
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factors (IGFs) stimulate the release of alpha 1-antichymotrypsin and soluble IGF-II/mannose 6-phosphate receptor from MCF7 breast cancer cells.
Confort C; Rochefort H; Vignon F
Endocrinology; 1995 Sep; 136(9):3759-66. PubMed ID: 7649082
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
13. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol.
Karey KP; Sirbasku DA
Cancer Res; 1988 Jul; 48(14):4083-92. PubMed ID: 3289739
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.
Sharoni Y; Bosin E; Miinster A; Levy J; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1648-51. PubMed ID: 2646641
[TBL] [Abstract][Full Text] [Related]
15. Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line.
Bradley LM; Gierthy JF; Pentecost BT
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):185-96. PubMed ID: 18337089
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
Braczkowski R; Schally AV; Plonowski A; Varga JL; Groot K; Krupa M; Armatis P
Cancer; 2002 Oct; 95(8):1735-45. PubMed ID: 12365022
[TBL] [Abstract][Full Text] [Related]
17. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
Yano T; Pinski J; Radulovic S; Schally AV
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
20. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
Reeve JG; Morgan J; Schwander J; Bleehen NM
Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
